0001209191-20-006298.txt : 20200204 0001209191-20-006298.hdr.sgml : 20200204 20200204161533 ACCESSION NUMBER: 0001209191-20-006298 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200131 FILED AS OF DATE: 20200204 DATE AS OF CHANGE: 20200204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SACHS BRUCE I CENTRAL INDEX KEY: 0001197036 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20573865 MAIL ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-31 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001197036 SACHS BRUCE I C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2020-01-31 4 M 0 20000 53.85 A 31210 D Common Stock 2020-01-31 4 S 0 1700 224.02 D 29510 D Common Stock 2020-01-31 4 S 0 1858 224.98 D 27652 D Common Stock 2020-01-31 4 S 0 4198 226.32 D 23454 D Common Stock 2020-01-31 4 S 0 5644 227.01 D 17810 D Common Stock 2020-01-31 4 S 0 300 227.66 D 17510 D Common Stock 2020-01-31 4 S 0 600 228.33 D 16910 D Common Stock 2020-01-31 4 S 0 500 229.90 D 16410 D Common Stock 2020-01-31 4 S 0 1200 230.87 D 15210 D Common Stock 2020-01-31 4 S 0 1200 232.04 D 14010 D Common Stock 2020-01-31 4 S 0 1800 233.13 D 12210 D Common Stock 2020-01-31 4 S 0 900 234.15 D 11310 D Common Stock 2020-01-31 4 S 0 100 235.40 D 11210 D Stock Option (Right to Buy) 53.85 2020-01-31 4 M 0 20000 0.00 D 2021-05-31 Common Stock 20000 0 D Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $224.02 (range $223.58 to $224.40). Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $224.98 (range $224.66 to $225.21). Open market sales reported on this line occurred at a weighted average price of $226.32 (range $225.62 to $226.60). Open market sales reported on this line occurred at a weighted average price of $227.01 (range $226.70 to $227.59). Open market sales reported on this line occurred at a weighted average price of $227.66 (range $227.62 to $227.70). Open market sales reported on this line occurred at a weighted average price of $228.33 (range $227.97 to $228.78). Open market sales reported on this line occurred at a weighted average price of $229.90 (range $229.16 to $230.12). Open market sales reported on this line occurred at a weighted average price of $230.87 (range $230.32 to $231.23). Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.45 to $232.42). Open market sales reported on this line occurred at a weighted average price of $233.13 (range $232.69 to $233.49). Open market sales reported on this line occurred at a weighted average price of $234.15 (range $233.77 to $234.66). Fully vested. /s/ Omar White, Attorney-in-Fact 2020-02-04